Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma
Journal of Clinical Oncology · 10.07.2026 · 44 (20) · 1889-1898
DOI: 10.1200/jco-25-03120 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.07.2026. Verfasst von Neha Mehta-Shah und 14 weiteren Autor:innen. Beteiligte Einrichtung: Washington University School of Medicine in St. Louis, Saint Louis, MO. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Peripheral, Purines, Isoquinolines, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Peripheral T-cell lymphomas (PTCLs) are rare, heterogeneous, aggressive lymphomas. Five-year overall survival (OS) remains approximately 30%-40%, and most patients will develop relapsed or refractory (R/R) disease. Duvelisib is an oral dual inhibitor of phosphatidylinositol 3-kinase (PI3K)-δ and PI3K-γ isoforms. Here, we report on the final analysis of the phase II PRIMO trial (ClinicalTrials.gov identifier: NCT03372057 ; Secura Bio, Inc) evaluating duvelisib monotherapy in R/R PTCL. METHODS PRIMO was conducted in two phases (dose optimization and dose expansion [PRIMO-EP]) at 45 centers globally. Eligible patients were age 18 years and older, had histologically confirmed diagnosis of PTCL, and had received ≥2 cycles of one standard regimen for PTCL. Based on dose optimization results, the selected regimen for PRIMO-EP was 75 mg twice a day for two cycles (to maximize disease control) followed by 25 mg twice a day (to reduce late toxicities), continued until progressive disease or unacceptable toxicity. RESULTS PRIMO-EP (N = 123) outcomes included independent review committee–assessed objective response rate (ORR): 48.0%, complete response rate (CRR): 33.3%, median progression-free survival (mPFS): 3.4 months, median OS (mOS): 12.4 months, and median duration of response (mDOR): 7.9 months. In the angioimmunoblastic T-cell lymphoma (AITL) subgroup, outcomes were ORR: 62.2%, CRR: 51.4%, mPFS: 8.3 months, mOS: 18.1 months, and mDOR: 11.3 months. Treatment-emergent adverse events (TEAEs; any grade) occurred in 120 patients (97.6%), and TEAEs grade ≥3 occurred in 91 patients (74.0%). TEAEs resulting in dose hold or dose reduction occurred in 44.7% and 9.8% of patients, respectively. CONCLUSION The PRIMO study demonstrates significant activity and tolerability of duvelisib in patients with R/R PTCL, most notably in the AITL subgroup. This provides strong rationale for further development in PTCL, and more specifically in the subgroup of nodal T-follicular helper cell lymphoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Washington University School of Medicine in St. Louis, Saint Louis, MO.
- IRCCS Azienda Ospedalierao-Universitaria di Bologna Istituto di Ematologia "Seràgnoli", Bologna, Italy.
- Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.
- Dana-Farber Cancer Institute, Boston, MA.
- Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
- Division of Hematology/Oncology, University of California, Los Angeles (UCLA), Los Angeles, CA.
ORCID-Profile: Neha Mehta-Shah, Pier Luigi Zinzani, Eric D Jacobsen, Monica Mead, Carla Casulo, Giuseppe Gritti, Koji Izutsu, David Sidransky, Ohad S Bentur, Christopher P Fox, Jonathan E Brammer, Steven M Horwitz
Zitieren
APA
Mehta-Shah, N., Zinzani, P. L., Jacobsen, E. D., Zain, J., Mead, M., Casulo, C., Gritti, G., Pinter-Brown, L., Izutsu, K., Sidransky, D., Bentur, O. S., Pro, B., Fox, C. P., Brammer, J. E., & Horwitz, S. M. (2026). Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma. Journal of Clinical Oncology, 44(20), 1889-1898. https://doi.org/10.1200/jco-25-03120
Vancouver
Mehta-Shah N, Zinzani PL, Jacobsen ED, Zain J, Mead M, Casulo C, et al. Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma. Journal of Clinical Oncology. 2026;44(20):1889-1898. doi:10.1200/jco-25-03120
BibTeX
@article{MehtaShah2026,
author = {Mehta-Shah, Neha and Zinzani, Pier Luigi and Jacobsen, Eric D and Zain, Jasmine and Mead, Monica and Casulo, Carla and Gritti, Giuseppe and Pinter-Brown, Lauren and Izutsu, Koji and Sidransky, David and Bentur, Ohad S and Pro, Barbara and Fox, Christopher P and Brammer, Jonathan E and Horwitz, Steven M},
title = {Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {20},
pages = {1889--1898},
doi = {10.1200/jco-25-03120}
}
EUVIMED